Skip to content
value.today

Innospec Inc.: financial analysis

Ratios worked out from 10 fiscal years of Innospec Inc.'s statements, compared with 94 companies in Chemicals.

Operating margin, 2025
7.3%
Chemicals: 4.4%
Return on equity, 2025
9.2%
Chemicals: 1.9%
Revenue growth, 3 years a year, 2025
-3.3%
Chemicals: -2.9%
Dividend yield, 2025
1.8%
Chemicals: 2.0%

Innospec Inc. scorecard#

Passes 16 of the 24 checks that could be worked out: strongest in financial health (3 of 3), weakest in growth (2 of 6). Fiscal year 2025; market cap of Oct 20, 2026.

  • Valuation4 of 5
    • ✓P/E below its peers' median17.2×P/E 17.2× against Chemicals's median of 23.1×.
    • ✓Price to book below its peers' median1.8×Price to book 1.8× against Chemicals's median of 2.1×.
    • ✓Price to sales below its peers' median1.3×Price to sales 1.3× against Chemicals's median of 1.8×.
    • ✗Free cash flow yield above 5%4.2%Free cash flow is 4.2% of the market value.
    • ✓Earnings yield above the 10-year Treasury yield5.8%Earnings yield 5.8% against the 10-year Treasury's 5.15% on 2026-11-13.
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth2 of 6
    • ✗Revenue grew in the newest year-3.6%Revenue down 3.6% in fiscal 2025.
    • ✗Revenue up more than 5% a year over three years-3.3%-3.3% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median-3.3%-3.3% a year against Chemicals's median of -2.9% (60 companies).
    • ✓Earnings per share grew in the newest year4.67 vs 1.42Diluted EPS 4.67 in fiscal 2025 against 1.42 the year before (report's currency).
    • ✓Net income higher than five years earlier$117 M$117 M in fiscal 2025 against $29 M in 2020.
    • ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2025.
  • Profitability3 of 5
    • ✓Profitable in the newest year$117 MNet income $117 M in fiscal 2025.
    • ✓Profitable in each of the last five years5 of 5Profitable in 5 of the five years to fiscal 2025.
    • ✓Operating margin above its peers' median7.3%7.3% against Chemicals's median of 4.4% (73 companies).
    • ✗Return on equity above 15%9.2%9.2% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✗Operating margin wider than three years earlier7.3%7.3% in fiscal 2025 against 9.5% in 2022.
  • Financial health3 of 3
    • ✓Short-term assets cover short-term liabilities2.8×Current ratio 2.79 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✓Cash from operations positive in each of the last three years3 of 3Positive in 3 of the three years to fiscal 2025.
    • ✓Altman Z-score outside the distress zone5.36Z-score 5.36 (safe zone) for fiscal 2025.
  • Shareholder returns4 of 5
    • ✓Pays a dividendYesPaid dividends in fiscal 2025.
    • ✓Dividend per share raised five years in a row5 of 5Dividend per share raised in 5 of the five years to fiscal 2025.
    • ✓Dividends under 75% of net income36.4%Dividends were 36.4% of net income in fiscal 2025.
    • ✓Share count up no more than 2% in a year-0.5%Diluted shares down 0.5% in fiscal 2025.
    • ✗Dividends and buybacks above 3% of the market value2.8%Dividends and buybacks were 2.8% of the market value.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Chemicals, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

What the 2025 statements show#

Each line is an observation with its numbers, not a judgement of the company.

Strengths

  • The dividend per share has been raised 12 years in a row.

Worth a look

  • Revenue fell 3.6% against the year before.

Piotroski F-score

Nine yes/no tests of whether the company's finances improved in the year. One point each.

6of 8(1 of the nine tests cannot be worked out from the statements on file, so there is no full score)
  • Made a profityes
  • Operations brought in cashyes
  • Return on assets roseyes
  • Cash from operations exceeds profityes
  • Long-term debt fell against assetsnot on file
  • Current ratio roseyes
  • No new shares issuedyes
  • Gross margin roseno
  • Asset turnover roseno

Altman Z-score

A 1968 formula that weighs five balance-sheet ratios. It was built on listed manufacturers and says less about other kinds of company.

5.36Safe zone(above 2.99, where the formula's author found few failures)
The five parts of the Altman Z-score
PartRatioWeightPoints
Working capital to assets0.35× 1.20.42
Retained earnings to assets0.60× 1.40.84
Operating income to assets0.07× 3.30.23
Market value to liabilities4.83× 0.62.90
Revenue to assets0.97× 10.97

Where the return on equity comes from

The DuPont split: margin, times how hard the assets work, times how much of them is financed by others.

Net margin6.6%Asset turnover1.00×Assets to equity1.40×Return on equity9.2%

Profitability#

Innospec Inc.: profitability by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Gross margin27.7%29.4%30.3%29.9%29.3%29.8%47%
Operating margin7.3%9.6%8.3%9.5%8.9%4.4%61%
Net margin6.6%1.9%7.1%6.8%6.3%2.1%75%
Return on equity9.2%3.0%12.7%12.9%9.4%1.9%73%
Return on assets6.5%2.1%8.4%8.4%6.3%0.8%81%
Return on invested capital—————8.9%—

Growth#

Innospec Inc.: growth by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Revenue growth-3.7%-5.3%-0.8%32.4%24.3%-0.8%33%
Revenue growth, 3 years a year-3.3%7.6%17.8%9.1%0.2%-2.9%49%
Revenue growth, 5 years a year8.3%4.1%5.7%8.5%10.9%5.2%80%
Net income growth227.5%-74.4%4.6%42.9%224.4%-4.2%95%
Earnings per share growth228.9%-74.5%4.5%41.9%223.3%-3.4%97%

Financial strength#

Innospec Inc.: financial strength by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Debt to equity—————0.64×—
Net debt—————$862 M—
Net debt to EBITDA—————2.77×—
Interest cover—————1.18×—
Current ratio2.79×2.58×2.38×2.15×2.16×2.22×68%
Equity share of assets72.4%69.8%67.2%64.7%65.7%48.9%84%

Cash#

Innospec Inc.: cash by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Cash conversion118.6%518.3%149.0%61.4%100.1%175.2%16%

Shareholder returns#

Innospec Inc.: shareholder returns by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Dividend yield1.8%————2.0%44%
Buyback yield1.0%————1.5%40%
Shareholder yield2.8%————2.7%53%
Dividend payout36.4%109.0%25.2%23.8%30.9%36.4%—
Change in share count-0.5%0.4%0.2%0.5%0.3%-0.1%64%

Efficiency#

Innospec Inc.: efficiency by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Asset turnover1.00×1.07×1.18×1.24×1.00×0.69×82%

How each figure is worked out#

Gross margin
Gross profit as a share of revenue.
Operating margin
Operating income as a share of revenue.
Net margin
Net income as a share of revenue.
Return on equity
Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
Return on assets
Net income as a share of total assets (average of the year).
Return on invested capital
Operating income after tax, as a share of debt plus equity less cash (average of the year). The tax rate is the year's own: income tax over pre-tax income.
Revenue growth
Revenue against the year before.
Revenue growth, 3 years a year
The yearly rate that takes revenue of three years earlier to this year's.
Revenue growth, 5 years a year
The yearly rate that takes revenue of five years earlier to this year's.
Net income growth
Net income against the year before. Only when both years were profitable.
Earnings per share growth
Diluted earnings per share against the year before. Only when both were positive.
Debt to equity
Total debt divided by shareholders' equity. Not given when equity is negative.
Net debt
Total debt less cash. Negative means more cash than debt.
Net debt to EBITDA
Debt less cash, divided by operating income plus depreciation and amortization: roughly the years of operating earnings needed to repay it.
Interest cover
Operating income divided by the interest paid on debt.
Current ratio
Assets due within a year divided by liabilities due within a year.
Equity share of assets
Shareholders' equity as a share of total assets.
Cash conversion
Cash from operations as a share of net income. Only when the year was profitable.
Dividend yield
Dividends paid in the fiscal year as a share of today's market value.
Buyback yield
Shares bought back in the fiscal year as a share of today's market value.
Shareholder yield
Dividends plus buybacks as a share of today's market value.
Dividend payout
Dividends paid as a share of net income. Only when the year was profitable.
Change in share count
Diluted shares against the year before. Negative: fewer shares.
Asset turnover
Revenue divided by total assets (average of the year).

Source: Innospec Inc.'s statements: annual reports filed with the SEC. Arithmetic on reported figures, in US dollars; nothing is estimated. A figure is blank when a line it needs is not in the statements on file, and left out when the result cannot be right (a margin from next to no revenue). "Ahead of" is the share of the 94 companies in Chemicals that Innospec Inc. is better than on that figure, using each company's newest fiscal year; yields use today's market value. Medians for every industry · Back to Innospec Inc.